Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immuno-PET for Clinical Theranostic Approaches.
Bailly C, Cléry PF, Faivre-Chauvet A, Bourgeois M, Guérard F, Haddad F, Barbet J, Chérel M, Kraeber-Bodéré F, Carlier T, Bodet-Milin C. Bailly C, et al. Int J Mol Sci. 2016 Dec 28;18(1):57. doi: 10.3390/ijms18010057. Int J Mol Sci. 2016. PMID: 28036044 Free PMC article. Review.
Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen x anti-hapten bispecific antibody-mediated pretargeting of Iodine-131-labeled hapten in a phase I radioimmunotherapy trial.
Kraeber-Bodéré F, Faivre-Chauvet A, Ferrer L, Vuillez JP, Brard PY, Rousseau C, Resche I, Devillers A, Laffont S, Bardiès M, Chang K, Sharkey RM, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3973S-81S. Clin Cancer Res. 2003. PMID: 14506196 Clinical Trial.
Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial.
Kraeber-Bodéré F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, Vuillez JP, Devillers A, Chang CH, Goldenberg DM, Chatal JF, Barbet J. Kraeber-Bodéré F, et al. J Nucl Med. 2006 Feb;47(2):247-55. J Nucl Med. 2006. PMID: 16455630 Free article. Clinical Trial.
Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group.
Chatal JF, Campion L, Kraeber-Bodéré F, Bardet S, Vuillez JP, Charbonnel B, Rohmer V, Chang CH, Sharkey RM, Goldenberg DM, Barbet J; French Endocrine Tumor Group. Chatal JF, et al. J Clin Oncol. 2006 Apr 10;24(11):1705-11. doi: 10.1200/JCO.2005.04.4917. Epub 2006 Mar 20. J Clin Oncol. 2006. PMID: 16549819 Clinical Trial.
Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancer patients with iodine-negative recurrence.
Curtet C, Carlier T, Mirallié E, Bodet-Milin C, Rousseau C, Barbet J, Kraeber-Bodéré F. Curtet C, et al. Eur J Nucl Med Mol Imaging. 2007 Oct;34(10):1556-62. doi: 10.1007/s00259-007-0393-6. Epub 2007 May 24. Eur J Nucl Med Mol Imaging. 2007. PMID: 17522858 Clinical Trial.
Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.
Oudoux A, Salaun PY, Bournaud C, Campion L, Ansquer C, Rousseau C, Bardet S, Borson-Chazot F, Vuillez JP, Murat A, Mirallié E, Barbet J, Goldenberg DM, Chatal JF, Kraeber-Bodéré F. Oudoux A, et al. J Clin Endocrinol Metab. 2007 Dec;92(12):4590-7. doi: 10.1210/jc.2007-0938. Epub 2007 Sep 18. J Clin Endocrinol Metab. 2007. PMID: 17878252 Clinical Trial.
193 results